{"product_id":"ashland-swot-analysis","title":"Ashland SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAshland’s SWOT highlights resilient specialty-chemicals expertise, diversified end-markets, and opportunities in sustainable solutions, alongside supply-chain and margin pressures from raw‑material volatility and cyclical demand—insights that matter to investors and strategists. Purchase the full SWOT analysis for a research-backed, editable Word and Excel package with detailed findings, financial context, and strategic recommendations to inform deals, pitches, and planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Value Specialty Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFollowing its strategic transformation, Ashland shifted to high-margin specialty chemicals and by Q4 2025 Life Sciences and Personal Care made ~68% of revenue, driving adjusted EBITDA margins above 18% and recurring sales from formulation-driven ingredients; these differentiated, essential inputs for pharma and beauty create a strong competitive moat, higher customer switching costs, and more resilient cash flow versus commodity exposures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Market Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAshland leads the global additives market, especially cellulose ethers for architectural coatings and pharma excipients, with 2025 revenues showing \u0026gt;70% of sales outside North America and chemical segment revenue of roughly $1.2B in FY2024 supporting scale and R\u0026amp;D.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustained Innovation Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy late 2025 Ashland exceeded its R\u0026amp;D targets, launching Viatel bioresorbable polymers and 12 other high-impact products, helping innovation-driven sales rise 18% y\/y and contributing to a 9% lift in adjusted EBITDA margin; the Globalize and Innovate strategy commercialized three new tech platforms focused on sustainability and performance, keeping Ashland as a preferred partner for advanced material solutions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Efficiency and Cost Discipline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAshland’s operational efficiency and cost discipline—anchored by a $30 million cost-reduction plan and a $60 million manufacturing network optimization—sustained EBITDA margins above 18% in 2024 despite volume headwinds, showing resilient profitability through self-help actions.\u003c\/p\u003e\n\u003cp\u003eThe manufacturing footprint was streamlined, reducing fixed costs and improving agility heading into 2026, with ongoing savings expected to boost free cash flow and margin resilience.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$30M cost reductions completed\u003c\/li\u003e\n\u003cli\u003e$60M manufacturing optimization\u003c\/li\u003e\n\u003cli\u003eEBITDA margin \u0026gt;18% in 2024\u003c\/li\u003e\n\u003cli\u003eImproved free cash flow and agility for 2026\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Dividend and Liquidity Profile\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs of December 31, 2025, Ashland has paid dividends for over 55 consecutive years, making it a reliable pick for income investors; the 2025 annual dividend totaled $1.80 per share (up 3% YoY).\u003c\/p\u003e\n\u003cp\u003eStrong liquidity underpins this payout: cash and equivalents were $620 million and total available liquidity exceeded $1.1 billion at year-end, while net leverage (net debt\/adjusted EBITDA) stood near 1.6x.\u003c\/p\u003e\n\u003cp\u003eThat balance sheet gives Ashland capital to pursue bolt-on acquisitions and continue share returns without stressing credit metrics.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e55+ years of consecutive dividends\u003c\/li\u003e\n\u003cli\u003e$1.80 annual dividend in 2025 (+3% YoY)\u003c\/li\u003e\n\u003cli\u003e$620M cash; $1.1B+ available liquidity\u003c\/li\u003e\n\u003cli\u003eNet leverage ~1.6x (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAshland: High‑margin LifeSci leader—\u0026gt;18% EBITDA, $1.2B chem, strong liquidity \u0026amp; dividends\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAshland’s strengths: high-margin Life Sciences\/Personal Care (~68% revenue in Q4 2025) driving adjusted EBITDA \u0026gt;18%; global scale with \u0026gt;70% sales outside North America and ~$1.2B chemical revenue (FY2024); successful R\u0026amp;D—Viatel and 12 products—lifting innovation sales +18% y\/y; $30M cost cuts + $60M manufacturing savings; strong liquidity ($620M cash, $1.1B+ available) and 55+ years dividends.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLifeSci\/PC rev (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e~68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChem rev (FY2024)\u003c\/td\u003e\n\u003ctd\u003e$1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash \/ Liquidity\u003c\/td\u003e\n\u003ctd\u003e$620M \/ $1.1B+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet leverage (2025)\u003c\/td\u003e\n\u003ctd\u003e~1.6x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT framework detailing Ashland’s internal strengths and weaknesses and the external opportunities and threats shaping its competitive position and strategic direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise Ashland SWOT snapshot for quick strategic alignment and executive decision-making, easily integrated into reports and slides.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecent Net and Operating Losses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite strong margins, Ashland reported an operating loss in Q4 2025, driven by one-time charges and portfolio optimization costs; adjusted operating margin remained positive at ~8.2% for FY 2025. The firm took a non-cash goodwill impairment exceeding $700 million in early 2025 after market cap fell below book value. These hits show Ashland is still in the final stages of a multi-year structural transition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExposure to Industrial Cyclicality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWhile Ashland’s Life Sciences and Personal Care units stayed stable, its Specialty Additives and Intermediates remained highly cyclical, tying results to construction and coatings demand.\u003c\/p\u003e\n\u003cp\u003eIn 2025 those segments saw persistent headwinds: North American construction starts fell ~8% year-over-year and global architectural coatings demand dropped ~6%, pressuring volumes.\u003c\/p\u003e\n\u003cp\u003eAs a result, segment earnings swung notably, driving a 12% quarter-to-quarter volatility in total adjusted EBITDA, since industrial demand tracks interest rates and global growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReduced Scale from Divestitures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe aggressive portfolio optimization, including the 2023 sale of the Nutraceuticals unit and 2024 divestiture of Avoca, cut Ashland’s revenue base—pro forma 2024 net sales fell roughly 18% to about $2.2 billion—reducing scale and diversification.\u003c\/p\u003e\n\u003cp\u003eMoody’s in 2024 warned the transactions increase reliance on fewer product lines, raising earnings volatility; segment-specific downturns could swing EBITDA by several percentage points.\u003c\/p\u003e\n\u003cp\u003eSmaller scale also weakens bargaining power: procurement leverage and pricing flexibility in key specialty-chemicals supply chains are now more constrained, risking margin pressure during raw-material shocks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational and Weather Disruptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eToward late 2025 and into early 2026, Ashland faced operational setbacks—Calvert City start-up delays and weather disruptions—that cut short-term volumes and forced management to narrow 2026 guidance, reducing expected adjusted EBITDA by an estimated $25–35 million for the first half of 2026.\u003c\/p\u003e\n\u003cp\u003eThese events show the risk of a concentrated manufacturing footprint: a single-site issue at Calvert City translated into a roughly 4–6% hit to quarterly sales in Q4 2025 versus plan, amplifying volatility in quarterly results.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCalvert City start-up delays\u003c\/li\u003e\n\u003cli\u003eWeather-related downtime\u003c\/li\u003e\n\u003cli\u003eGuidance narrowed; adj. EBITDA impact $25–35M\u003c\/li\u003e\n\u003cli\u003eQuarterly sales hit ~4–6%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePricing and Volume Pressures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAshland has faced unfavorable pricing and volume declines in high-competition pockets, cutting margins; Q3 2025 Intermediates revenue fell about 9% year-over-year, driven by a 14% drop in BDO merchant volumes.\u003c\/p\u003e\n\u003cp\u003eTrough-like conditions in Intermediates and weaker merchant demand pushed segment adjusted EBITDA margin down roughly 350 basis points versus 2024, pressuring free cash flow.\u003c\/p\u003e\n\u003cp\u003eManagement must balance price discipline with volume growth; restoring merchant volumes to 2023 levels (about +18%) would be needed to recover prior margin run-rates.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ3 2025 Intermediates rev -9% YoY\u003c\/li\u003e\n\u003cli\u003eBDO merchant volumes -14% YoY\u003c\/li\u003e\n\u003cli\u003eAdj. EBITDA margin -350 bps vs 2024\u003c\/li\u003e\n\u003cli\u003eNeed ~+18% volumes to regain 2023 margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAshland hit by $700M goodwill write‑down, volumes slump and narrowed FY25 margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAshland’s 2025 restructuring and one-time charges drove an operating loss and \u0026gt;$700M goodwill impairment; FY25 adjusted margin ~8.2%. Cyclical Additives\/Intermediates saw volumes fall (Q3 2025 Intermediates -9% YoY; BDO volumes -14%), cutting segment EBITDA margin ~350bps vs 2024. Portfolio sales trimmed pro forma 2024 net sales ~18% to ~$2.2B, raising concentration and supply-chain pricing risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGoodwill write-down\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$700M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY25 adj. margin\u003c\/td\u003e\n\u003ctd\u003e~8.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePro forma 2024 sales\u003c\/td\u003e\n\u003ctd\u003e~$2.2B (-18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Intermediates rev\u003c\/td\u003e\n\u003ctd\u003e-9% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBDO volumes\u003c\/td\u003e\n\u003ctd\u003e-14% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA margin hit\u003c\/td\u003e\n\u003ctd\u003e-350bps vs 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eAshland SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is pulled from the final, editable file. You’re viewing a live preview of the real document; the complete, detailed version becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752820781433,"sku":"ashland-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ashland-swot-analysis.png?v=1772246000","url":"https:\/\/matrixbcg.com\/products\/ashland-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}